| Name | Title | Contact Details |
|---|
Kersia Group is a global leader in biosecurity and food safety, focused on ensuring the safety of food production, processing, distribution, and consumption. The company aims to create a food-safe world by providing innovative and sustainable solutions that prevent diseases and contamination throughout the food supply chain. Kersia offers a variety of services to enhance food safety and operational performance. These include plant sanitation assessments, inventory usage management, annual cleaning validation, routine plant visits, and sanitation audits. The company collaborates with clients to optimize sanitation programs, ensuring high hygiene standards and compliance with regulatory requirements. With a significant presence in the United States and headquartered in France, Kersia USA specifically addresses food safety challenges in the meat and poultry processing sectors. The company is dedicated to supporting various industries, including dairy and healthcare, by delivering tailored solutions that enhance operational efficiency.
Weekes Forest Products, Inc. (WEEKES) is a St. Paul, Minnesota based wholesaler and distributor of wood products and building materials. Founded in 1978, WEEKES has grown to become one of the most successful independently-owned distributors in the United States. Financial Data. WEEKES has earned a reputation as a highly entrepreneurial, sales-driven company with a history of financial success. WEEKES has 8 regional locations. Seven of these enterprises were the result of acquisitions WEEKES has completed since 1986. In the United States, many local and regional distribution companies could add to WEEKES growth. The Company plans to grow internally as well as through future acquisition(s). WEEKES FOREST PRODUCTS LOCATIONS Fargo, ND 800-548-2479 St. Paul, MN 800-328-2890 Green Bay, WI 800-236-6314 Milwaukee, WI 800-222-4698 Chicago, IL 800-398-8266 Grand Rapids, MI 800-442-8082 Tampa, FL-Logan Lumber Co. 800-365-5545 Corporate Culture. WEEKES is an informal, value-driven company where honesty, straight communication, and mutual respect are important. Teamwork, good product knowledge, strong work ethic and cost control are keys to the success of the company.
Autonomous Solutions, Inc. (ASI) is a leader in industrial vehicle automation, focusing on retrofitting existing equipment with autonomous technology. Founded in 2000 and based in Petersboro, Utah, ASI operates a 100-acre proving ground for robotics testing. The company provides OEM/vendor-independent automation solutions for various sectors, employing between 201 and 500 staff and serving clients across six continents. ASI offers a range of products and services, including the Mobius® Fleet Management System for coordinating autonomous fleets and custom automation kits for vehicles of all sizes. Their solutions cater to multiple industries, such as mining, automotive, agriculture, military, construction, logistics, security, and research. Notable clients include Ford Motor Company, Anglo American, John Deere, and the U.S. Department of Defense. ASI emphasizes all-weather, 24/7 operation, enhancing efficiency and reducing costs in applications like landscaping.
Accelerant is a data-driven risk exchange connecting specialty insurance underwriters with risk capital providers. Founded in 2018 by a group of longtime insurance industry executives and technology experts, our vision is to rebuild the way risk is exchanged – so that it works better, for everyone. For the underwriters we call Members, we deliver a full service offering that includes insights and analytics, distribution management, operational resources, and stable underwriting capacity. Our approach frees our Members to focus on profitable underwriting while growing their businesses. Our portfolio presents attractive, validated, and diversified source of specialty insurance premium to our risk capital provider partners.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.